Biophytis Annual General Meeting 2025
COMBINED GENERAL MEETING OF 13 NOVEMBER, 2025 Notice of meeting Download the document Amended notice of meeting Download the document Convocation Brochure Download the document
DetailsLetter to shareholders
Biophytis has published a letter to shareholders to share its progress to 2024 and its strategic outlook for 2025. Fullscreen Mode
DetailsObesity: OBA Clinical Program
Muscle loss due to obesity treatment: no therapy available today Worldwide, around 1 billion people live with obesity. Obesity is a chronic disease characterized by an excessive amount of body fat that disrupts the body’s normal function. The World Health Organization defines obesity as having a Body Mass Index (BMI) of 30 or higher. Obesity…
DetailsBiophytis Annual General Meeting 2024
COMBINED GENERAL MEETING OF 24 JUNE, 2024 Consolidated results of the AGM vote Download the document Consolidated result of the EGM vote Download the document Notice of meeting Download the document Notice of meeting brochure Télécharger le document Postal voting form Télécharger le document Access map Télécharger le document Statutory auditors’ report on regulated agreements…
Details2024
2024 BIO101 + GLP-1RA to prevent potential muscle loss in patients with overweight and obesity: the OBA study, Rob van Maanen MD MBA, Chief Medical Officer, SCWD 2024, Washington DC, USA BIO101: a drug candidate to reduce GLP-1RA-induced muscle mass or function loss in patients with obesity, Rob Van Maanen, Claudia Ferreira, Mathilde Latil, Serge…
DetailsDisclaimer October 2023
DISCLAIMER OCTOBER 2023 Les pages suivantes contiennent des informations relatives à l’offre au public de Biophytis. Ces informations ne sont pas destinées ou accessibles aux personnes résidant au Royaume-Uni, aux Etats-Unis, au Royaume-Uni, en Australie, au Canada ou au Japon. En conséquence, nous vous prions de remplir les champs ci-dessus pour accéder aux pages suivantes.…
Details